Nova Pharma Solutions Bhd (XKLS:03006) Cash And Cash Equivalents : RM3.74 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Nova Pharma Solutions Bhd Cash And Cash Equivalents?

Nova Pharma Solutions Bhd's quarterly cash and cash equivalents increased from Dec. 2022 (RM1.75 Mil) to Jun. 2023 (RM3.15 Mil) and increased from Jun. 2023 (RM3.15 Mil) to Dec. 2023 (RM3.74 Mil).

Nova Pharma Solutions Bhd's annual cash and cash equivalents declined from Dec. 2021 (RM2.02 Mil) to Dec. 2022 (RM1.75 Mil) but then increased from Dec. 2022 (RM1.75 Mil) to Dec. 2023 (RM3.74 Mil).

Nova Pharma Solutions Bhd Cash And Cash Equivalents Historical Data

The historical data trend for Nova Pharma Solutions Bhd's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Pharma Solutions Bhd Cash And Cash Equivalents Chart

Nova Pharma Solutions Bhd Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

7.22

0.25

2.02

1.75

3.74

Nova Pharma Solutions Bhd Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial											2.02	1.81	1.75	3.15	3.74

Nova Pharma Solutions Bhd Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nova Pharma Solutions Bhd (XKLS:03006) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nova Pharma Solutions Bhd Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nova Pharma Solutions Bhd's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Pharma Solutions Bhd (XKLS:03006) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Construction » Nova Pharma Solutions Bhd (XKLS:03006) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

N/A

Address

Jalan USJ 25/1, Level 5, Suite C-5-1 & 2, Block C, Sky Park, One City, Subang Jaya, SGR, MYS, 47650

Website

http://www.novapharmasolutions.com

Nova Pharma Solutions Bhd provides engineering solutions to pharma and biotech industries. The company's reportable segments include Design fee, Post Design, & Other support fees. Design fee comprises conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipment and processes. Post design fee comprise tendering and procurement support as well as the construction of a plant, & Other support fees comprise of services to assist a customer in the good manufacturing practice document review & gap analysis and assessment. It generates a majority of its revenue from the Design fee segment. Geographically, the company generates a majority of its revenue from Malaysia.

Nova Pharma Solutions Bhd (XKLS:03006) Headlines

No Headlines